Search

everythinglearnresearchcommunity

for

Search:↓

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.

Topical tacrolimus reduces certain growth factors in hair follicles.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.

Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

Cyclosporin A is highly toxic to rats, causing severe health issues and death.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Systemic agents like cyclosporine, methotrexate, and acitretin help manage psoriasis but have significant side effects.

The treatment was effective for lupus nephritis with manageable side effects.

Regulatory T cells and mesenchymal stem cells work together to prevent immune system overreactions and tissue damage.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.

Topical corticosteroids can help treat severe alopecia areata when other treatments fail.

Some treatments for inflammatory bowel disease can cause skin problems like rashes and melanoma.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Cyclosporine cleared a woman's resistant skin condition quickly and kept it away for over a year.

Azathioprine caused side effects in over half of the Korean pediatric inflammatory bowel disease patients, requiring close monitoring.

A 5-year-old boy's skin condition improved with systemic valganciclovir after a cardiac transplant and immunosuppressive therapy.

A woman experienced hair loss, nail changes, bone marrow suppression, and low blood protein after taking azathioprine.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Pharmaceutical care in transplantation faces challenges but has promising future opportunities for better outcomes.

Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.